CanSino Biologics Inc (CJH) — Strategic Asset Allocation Index
CanSino Biologics Inc (CJH) has a Strategic Asset Allocation Index of 47.8% as of June 2023. Strategic assets (PP&E of €2.85 Billion plus long-term investments of €-) total €2.85 Billion, measured against net assets of €5.97 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See net asset quality index of CanSino Biologics Inc to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
CanSino Biologics Inc Strategic Asset Allocation Index (2016–2022)
This chart shows how CanSino Biologics Inc's Strategic Asset Allocation Index has evolved across 7 annual periods from 2016 to 2022. As of June 2023, the index stands at 47.8%, representing strategic assets of €2.85 Billion against net assets of €5.97 Billion EUR. For live market cap and overall valuation, see market cap of CanSino Biologics Inc.
Annual Strategic Asset Allocation Index for CanSino Biologics Inc (2016–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for CanSino Biologics Inc from 2016 to 2022, covering 7 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See CJH net asset value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 42.4% | €3.07 Billion | €3.07 Billion | €- | €7.25 Billion | ▲ +16.4 pp |
| 2021 | 26.0% | €2.22 Billion | €2.22 Billion | €- | €8.55 Billion | ▲ +11.6 pp |
| 2020 | 14.4% | €873.95 Million | €873.95 Million | €- | €6.07 Billion | ▼ -24.7 pp |
| 2019 | 39.1% | €574.89 Million | €574.89 Million | €- | €1.47 Billion | ▼ -61.9 pp |
| 2018 | 101.0% | €507.45 Million | €507.45 Million | €- | €502.32 Million | ▲ +35.7 pp |
| 2017 | 65.4% | €396.89 Million | €396.89 Million | €- | €607.33 Million | ▼ -8.4 pp |
| 2016 | 73.8% | €158.18 Million | €158.18 Million | €- | €214.47 Million | — |